NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.

1. Non-Small Cell Lung Cancer Pipeline
Insight, Pipeline Assessment, Pipeline Drug
"Non-Small Cell Lung Cancer Pipeline Insight, 2020" report by DelveInsight outlays comprehensive
insights of present clinical development scenario and growth prospects across the Non-Small Cell
Lung Cancer market. A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is
provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment
guidelines.
The assessment part of the report embraces in-depth Non-Small Cell Lung Cancer commercial
assessment and clinical assessment of the Non-Small Cell Lung Cancer pipeline products from the
pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the
drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any),
and product development activities comprising the technology, Non-Small Cell Lung
Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-
related details.
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late
stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi
(Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar
(Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua
(Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi
(Larotrectinib), Portrazza (Necitumumab) along with many more.

2. Drugs covered in the report are:-
There are several key players robustly involved in developing potential products such as
 Nazartinib (EGF816)
 Capmatinib (INC280)
 Tepmetko (tepotinib)
 Merestinib
 JNJ-61186372 (JNJ-6372)
 Vemurafenib Plus Cobimetinib
 X-396 (Ensartinib)
 Tedopi (OSE2101)
 Selpercatinib (LY3527723/ LOXO-292)
 SAR408701
 Braftovi (encorafinib) + Mektovi (binimetinib)
 PADCEV (enfortumab vedotin/ASG-22ME)
 Pralsetinib (BLU-667)
 TAK-788: Canakinumab (ACZ885)
 Avelumab (Bavencio)
 Veliparib (ABT-888): Sitravatinib (MGCD516)
 Tesevatinib
 Romiplostim: Cabozantinib
 Sym015
 AMG 510
 INCMGA00012 (MGA012)
 Libtayo (Cemiplimab)
 Bavituximab
 M7824 (Bintrafusp alfa)
 And many others
Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-
pipeline-insight

3. Key Players covered in the report are:-
 Novartis Pharmaceuticals
 Merck KGaA
 Eli Lilly and Company
 Janssen Research & Development
 Hoffmann-La Roche
 Xcovery
 BeyondSpring Pharmaceuticals
 OSE Immunotherapeutics
 Sanofi
 Pfizer
 Astellas Pharma
 Seattle Genetics
 Blueprint Medicines Corporation
 Takeda
 AbbVie
 Kadmon Corporation
 Amgen
 Symphogen
 Regeneron Pharmaceuticals
 Peregrine Pharmaceuticals
 Avid Bioservices
 GlaxoSmithKline
And many others
The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution
of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-
L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR,
Total Market Size of ALK as well.
Market Driver

4. Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-
pipeline-insight
Market Barrier
Key Questions Answered
 What will be the growth opportunities in the 7MM with respect to the patient population
pertaining to Non-Small Cell Lung Cancer?
 What are the key findings pertaining to the Non-Small Cell Lung Cancer epidemiology across
7MM and which country will have the highest number of patients during the forecast period
(2017-2030)?
 What would be the total number of patients of Non-Small Cell Lung Cancer across the 7MM
during the forecast period (2017-2030)?
 Among the EU5 countries, which country will have the highest number of patients during the
forecast period (2017-2030)?
 At what CAGR the patient population is expected to grow in 7MM during the forecast period
(2017-2030)?
 What is the disease risk, burden and unmet needs of the Non-Small Cell Lung Cancer?
 What are the currently available treatments of Non-Small Cell Lung Cancer?
Reasons to buy
 The Non-Small Cell Lung Cancer Epidemiology report will allow the user to -
 Develop business strategies by understanding the trends shaping and driving the global Non-
Small Cell Lung Cancer market
 Quantify patient populations in the global Non-Small Cell Lung Cancer market to improve
product design, pricing, and launch plans
 Organize sales and marketing efforts by identifying the age groups and sex that present the
best opportunities for Non-Small Cell Lung Cancer therapeutics in each of the markets
covered

5.  Understand the magnitude of Non-Small Cell Lung Cancer population by its epidemiology
 The Non-Small Cell Lung Cancer Epidemiology Model developed by DelveInsight is easy to
navigate, interactive with dashboards, and epidemiology based with transparent and
consistent methodologies. Moreover, the model supports data presented in the report and
showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
 Patient Segmentation
 Disease Risk and Burden
 Risk of disease by the segmentation
 Factors driving growth in a specific patient population
Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-
pipeline-insight
Table of Contents
1. Report Introduction
2. Non-Small Cell Lung Cancer
2.1. Overview
2.2. History
2.3. Non-Small Cell Lung Cancer Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Non-Small Cell Lung Cancer Diagnosis
2.6.1. Diagnostic Guidelines
3. Non-Small Cell Lung Cancer Current Treatment Patterns
3.1. Non-Small Cell Lung Cancer Treatment Guidelines
4. Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Non-Small Cell Lung Cancer companies collaborations, Licensing, Acquisition -Deal Value
Trends

6. 4.1.1.1. Assessment Summary
4.1.2. Non-Small Cell Lung Cancer Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Non-Small Cell Lung Cancer Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Non-Small Cell Lung Cancer Late Stage Products (Phase-III)
7. Non-Small Cell Lung Cancer Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Small Cell Lung Cancer Discontinued Products

7. 13. Non-Small Cell Lung Cancer Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Non-Small Cell Lung Cancer Key Companies
15. Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Non-Small Cell Lung Cancer Unmet Needs
18. Non-Small Cell Lung Cancer Future Perspectives
19. Non-Small Cell Lung Cancer Analyst Review

8. 20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Request a Webex Demo to get a walk-through of the
report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market
Related Reports:
 Non-Small Cell Lung Cancer Epidemiology Forecast to 2030
 Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2020
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the
life science segment. With a wide array of smart end-to-end solutions, the firm helps the global
Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for
improving their performances to stay ahead of the competitors.